A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients

Exogenous arginine is required for growth in some argininosuccinate synthetase (ASS)-deficient cancers. Arginine deiminase (ADI) inhibits growth in various ASS-deficient cancers by depleting arginine. The efficacy of pegylated ADI (ADI-PEG20) in relapsed/refractory/poor-risk acute myeloid leukemia (...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Hui-Jen, Jiang, Shih Sheng, Hung, Wen-Chun, Borthakur, Gautam, Lin, Sheng-Fung, Pemmaraju, Naveen, Jabbour, Elias, Bomalaski, John S., Chen, Ya-Ping, Hsiao, Hui-Hua, Wang, Ming-Chung, Kuo, Ching-Yuan, Chang, Hung, Yeh, Su-Peng, Cortes, Jorge, Chen, Li-Tzong, Chen, Tsai-Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595917/
https://www.ncbi.nlm.nih.gov/pubmed/28900115
http://dx.doi.org/10.1038/s41598-017-10542-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595917/
https://www.ncbi.nlm.nih.gov/pubmed/28900115
http://dx.doi.org/10.1038/s41598-017-10542-4

Ejemplares similares